In this issue, there are 2 excellent large retrospective studies from single centers in Groningen, The Netherlands,1 and Haifa, Israel2 of patients referred for possible bullous pemphigoid (BP). In addition, there is a nationwide population-based study from Korea evaluating the risk of BP in patients with diabetes receiving dipeptidyl peptidase 4 inhibitors (gliptins).3